Johnson & Johnson (JNJ): FY24 Q4 earnings call, Jan 22, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jan 22, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Vaccine”; 4 quoted, at least 25 words apart.
…year, we delivered robust operational sales growth of 7% excluding the COVID-19 vaccine. With SPRAVATO surpassing $1 billion in annual sales, we now have 26…
…points due to the loss of exclusivity of STELARA and the COVID-19 vaccine. Turning now to earnings. For the quarter, net earnings were $3.4 billion…
…the US and 2.9% outside of the US. STELARA and the COVID-19 vaccine negatively impacted worldwide growth by 260 basis points. Acquisition and divestitures positively…
…Innovative Medicine. Worldwide sales of $14.3 billion increased 6.5% excluding the COVID-19 vaccine with growth of 11.1% in the US and a decline of 0.3%…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-01-22:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-01-22:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP